The construction of Britain’s very first laboratory skyscraper will begin on Tuesday in Canary Wharf (east London) with the goal of providing more space for scientists. A partnership between Canary Wharf Group, a Dutch developer and Kadans Science Partner is developing the building at North Quay, Europe’s highest purpose-built lab building.
The “vertical campus”, a 23-storey building with 823,000 square feet, is intended to expand the local life sciences cluster, which includes the Medicines and Healthcare products Regulatory Agency and Genomics England. The building will open in 2027. It will include common areas that encourage collaboration.
The lack of labs in the “Golden Triangle”, which includes London, Oxford, and Cambridge as one of the leading clusters of the world, is believed to be a major obstacle for the growth of small and start-up businesses.
Michel Leemhuis said that the UK government has identified life sciences as a key partner in its plans for positive change and economic development.
One North Quay is a building designed by KPF and expected to be finished in 2027. It will feature many common areas that are located throughout the spine to encourage collaboration. The building will have a rooftop bar and restaurant as well as a cafe on the ground floor.
Shobi Khan is the chief executive officer of Canary Wharf Group. He manages the departure of important tenants in the financial sector, such as HSBC. The development was part of the group’s strategy to “create a vibrant mixed-use urban community with 16.5 acres green space and waterside living. There are also over 350 shops and restaurants, as well as a growing amenities and leisure offering, and a calendar of events throughout the year.
Post Disclaimer
The following content has been published by Stockmark.IT. All information utilised in the creation of this communication has been gathered from publicly available sources that we consider reliable. Nevertheless, we cannot guarantee the accuracy or completeness of this communication.
This communication is intended solely for informational purposes and should not be construed as an offer, recommendation, solicitation, inducement, or invitation by or on behalf of the Company or any affiliates to engage in any investment activities. The opinions and views expressed by the authors are their own and do not necessarily reflect those of the Company, its affiliates, or any other third party.
The services and products mentioned in this communication may not be suitable for all recipients, by continuing to read this website and its content you agree to the terms of this disclaimer.